Caribou Biosciences (CRBU) Projected to Announce Quarterly Earnings on Wednesday

Caribou Biosciences (NASDAQ:CRBU) is expected to be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Caribou Biosciences to post earnings of ($0.27) per share and revenue of $1.60 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.28 million. On average, analysts expect Caribou Biosciences to post ($1.07) EPS for the current fiscal year and ($0.73) EPS for the next fiscal year.

Caribou Biosciences Stock Performance

Caribou Biosciences stock traded down $0.00 during mid-day trading on Wednesday, reaching $0.46. The stock had a trading volume of 32,315 shares, compared to its average volume of 1,894,024. The stock’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.62. Caribou Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $2.49. The firm has a market capitalization of $49.10 million, a PE ratio of -0.42 and a beta of 2.50.

Analyst Ratings Changes

Several research firms have recently issued reports on CRBU. Bank of America lowered their price target on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Royal Bank Of Canada cut shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price on the stock. in a report on Wednesday, October 7th. Leerink Partners downgraded Caribou Biosciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $4.00 to $1.00 in a research report on Wednesday, October 7th. Brookline Capital Markets lowered Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 7th. Finally, Wall Street Zen cut Caribou Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.50.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments.

Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.